Back to search results

Evaluating Questionnaires for Radiation Side Effects

This observational study aims to understand how different questionnaires measure side effects from radiation therapy (RT). We are looking for 300 participants who have been diagnosed with head and neck cancer (HNC) and are either currently receiving curative RT or have completed it within the last 5 years at MD Anderson. You must be 18 years or older and speak English. The study involves completing questionnaires like MDASI-HN, EORTC QLQ-C30, and EORTC HN35. The main goal is to see how well these different questionnaires compare to each other in measuring your symptoms and experiences with radiation side effects. The study's success will be measured by understanding the safety and adverse events (AEs) you report over about one year.

Study design
This is an observational study with a planned enrollment of 300 participants. It is not a drug trial, but rather evaluates different questionnaires.
What's involved
You would complete surveys, including the MDASI-HN, EORTC QLQ-C30, and EORTC HN35 questionnaires, of your own volition.
Compensation
Not stated in the trial record.
Follow-up
Your safety and adverse events will be measured through study completion, which is an average of one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06295783

Prospective Evaluation of the Relation Between Different Questionnaires Measuring Radiation-induced Side-effect

Recruiting
Not specifiedAges 18+Observational
M.D. Anderson Cancer Center
~300 participants
Updated 2026-07-14 on ClinicalTrials.gov
What's tested:MDASI-HNEORTC QLQ-C30EORTC HN35

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and adverse events (AEs)
Measured over Through study completion; an average of 1 year

Conditions

Radiation

Explore related trials

Malignant Head and Neck Neoplasm

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Amy Moreno, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Amy Moreno, MD
[email protected]
(713) 745-4590
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years
English as a primary language
Participants with a diagnosis of HNC undergoing active curative RT or having received curative RT within the past 5 years at MD Anderson
Ability to complete the survey(s) of their own volition

Exclusion

Age \< 18 years
Non-English speaking participants
Participants who are receiving or have received RT in a non-HN site.
Participants in follow up and over 5 years from post-treatment
Neurocognitive deficits that render patients unable to complete the survey(s) on their own.

What this trial measures

  • Safety and adverse events (AEs)Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)